SCHEMBL6708045

SCHEMBL6708045

CC(C)(CN[C@H](Cc1ccccc1)C(=O)O)OC(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
MME P08473 2/20 0.44
ACE2 Q9BYF1 1/20 0.44
ITGA4 P13612 1/20 0.44
ITGB7 P26010 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CTSS P25774 2/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSK P43235 1/20 0.43
FPR2 P25090 2/20 0.42
APP P05067 1/20 0.42
ATM Q13315 1/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
REN P00797 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706849 1.00 ACE (0.46) ACENPSR1ALDH1A1MAPTMME
SCHEMBL6706558 0.85 PPARA (0.55) ACEMMECTSS
Hydrochloric Acid SCHEMBL31684060 0.83 NPSR1 (0.47) ACENPSR1ALDH1A1MAPTMME
SCHEMBL20272503 0.81 NPSR1 (0.53) ACENPSR1ALDH1A1MAPTMME
SCHEMBL7191200 0.77 ATM (0.47) ALDH1A1KMT2AATMLMNA
SCHEMBL7596254 0.76 MME (0.57) ACENPSR1MMEACE2L3MBTL1
SCHEMBL12207239 0.76 MME (0.57) ACENPSR1MMEACE2L3MBTL1
SCHEMBL29260783 0.76 L3MBTL1 (0.51) ACENPSR1ALDH1A1MAPTMME
SCHEMBL6770155 0.75 ACE (0.54) ACENPSR1ALDH1A1MMEFPR2
SCHEMBL2476918 0.75 ACE (0.54) ACENPSR1ALDH1A1MAPTMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831084-B1 Agonism and antagonism; neuroprotection; strokes including thromboembolic and focal, global or tranient ischemic attack WYETH 2004-12-14 US disclosed
US-6828324-B2 Provide neuroprotection and prevent, inhibit or limit processes of neurodegeneration in mammals WYETH 2004-12-07 US disclosed
US-20040162430-A1 Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT 1A activity WYETH (US) 2004-08-19 US disclosed
EP-1276731-A2 BRANCHED ADAMANTYL AND NORADAMANTYL ARYL- AND ARALKYLPIPERAZINES WITH SEROTONIN 5-HT 1A ACTIVITY Wyeth (US) 2003-01-22 EP disclosed
WO-2001034586-A2 BRANCHED ADAMANTYL AND NORADAMANTYL ARYL- AND ARALKYLPIPERAZINES WITH SEROTONIN 5-HT1A ACTIVITY WYETH (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162430-A1 Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT 1A activity HTR1A, HTR5A, PARL ACE 3059/4885NPSR1 236/4885ALDH1A1 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.